FindTrial
Sign In

Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma

Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01265147
Enrollment
20
Registered
2010-12-23
Start date
2011-01-31
Completion date
2017-12-31
Last updated
2011-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Brief summary

This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.

Interventions

DRUGCisplatin

40mg/m2/w

DRUGNedaplatin

40mg/m2/w

Sponsors

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Age≥18,T1-2aN1-3;T2-4NxNPC,VEGFR+,++,KPS\>70,Life expectancy≥6 months, No uncontrolled hypertension,cardiac failure,diabetes,lunacy

Exclusion criteria

Distant metastasis, recurrent disease

Design outcomes

Primary

MeasureTime frameDescription
locoregionally control rate3 months3 months after treatment

Secondary

MeasureTime frameDescription
Survival1,3,5 years1 year Progress Free Survival,Disease Free Survival,3 years and 5 years Over All Survival,Safety

Countries

China

Contacts

Primary ContactZhenzhou Yang, Dr.
yangzhenzhou@sohu.com86(23)68757182

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026